X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs MERCK LTD - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD MERCK LTD BIOCON LTD/
MERCK LTD
 
P/E (TTM) x 92.4 50.9 181.3% View Chart
P/BV x 7.8 7.7 101.8% View Chart
Dividend Yield % 0.1 0.4 40.2%  

Financials

 BIOCON LTD   MERCK LTD
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
MERCK LTD
Dec-16
BIOCON LTD/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs1,1881,060 112.1%   
Low Rs305623 49.0%   
Sales per share (Unadj.) Rs68.7632.4 10.9%  
Earnings per share (Unadj.) Rs7.645.7 16.5%  
Cash flow per share (Unadj.) Rs14.062.3 22.4%  
Dividends per share (Unadj.) Rs1.0011.00 9.1%  
Dividend yield (eoy) %0.11.3 10.2%  
Book value per share (Unadj.) Rs86.3388.8 22.2%  
Shares outstanding (eoy) m600.0016.60 3,614.5%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.91.3 816.4%   
Avg P/E ratio x98.918.4 537.0%  
P/CF ratio (eoy) x53.413.5 395.7%  
Price / Book Value ratio x8.62.2 399.5%  
Dividend payout %13.224.1 55.0%   
Avg Mkt Cap Rs m447,90013,969 3,206.4%   
No. of employees `0006.11.6 388.4%   
Total wages/salary Rs m9,3111,487 626.3%   
Avg. sales/employee Rs Th6,705.86,631.9 101.1%   
Avg. wages/employee Rs Th1,514.2939.2 161.2%   
Avg. net profit/employee Rs Th736.9479.4 153.7%   
INCOME DATA
Net Sales Rs m41,23410,498 392.8%  
Other income Rs m2,062242 850.7%   
Total revenues Rs m43,29610,741 403.1%   
Gross profit Rs m8,2911,135 730.3%  
Depreciation Rs m3,851276 1,397.8%   
Interest Rs m6150-   
Profit before tax Rs m5,8871,102 534.1%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,569343 457.0%   
Profit after tax Rs m4,531759 597.0%  
Gross profit margin %20.110.8 185.9%  
Effective tax rate %26.731.1 85.6%   
Net profit margin %11.07.2 152.0%  
BALANCE SHEET DATA
Current assets Rs m41,4866,410 647.3%   
Current liabilities Rs m21,4138,828 242.5%   
Net working cap to sales %48.7-23.0 -211.3%  
Current ratio x1.90.7 266.9%  
Inventory Days Days6458 110.9%  
Debtors Days Days9438 245.3%  
Net fixed assets Rs m50,6611,406 3,602.2%   
Share capital Rs m3,000166 1,807.2%   
"Free" reserves Rs m48,8086,286 776.5%   
Net worth Rs m51,8086,455 802.7%   
Long term debt Rs m17,8980-   
Total assets Rs m99,8978,828 1,131.6%  
Interest coverage x10.6NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.41.2 34.7%   
Return on assets %5.28.6 59.9%  
Return on equity %8.711.8 74.4%  
Return on capital %9.617.1 56.4%  
Exports to sales %08.3 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA869 0.0%   
Imports (cif) Rs mNA2,209 0.0%   
Fx inflow Rs m12,058959 1,257.6%   
Fx outflow Rs m7,3482,612 281.3%   
Net fx Rs m4,710-1,653 -284.9%   
CASH FLOW
From Operations Rs m6,6211,070 618.6%  
From Investments Rs m-6,840-750 912.4%  
From Financial Activity Rs m-2,397-150 1,600.1%  
Net Cashflow Rs m-2,612171 -1,528.4%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 51.8 39.8%  
Indian inst/Mut Fund % 8.4 18.2 46.2%  
FIIs % 10.7 1.0 1,070.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 29.1 68.4%  
Shareholders   109,995 28,591 384.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare BIOCON LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Sep 21, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS